Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.06
ACOR's Cash to Debt is ranked higher than
55% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. ACOR: 1.06 )
ACOR' s 10-Year Cash to Debt Range
Min: 1.06   Max: 62.66
Current: 1.06

1.06
62.66
Equity to Asset 0.50
ACOR's Equity to Asset is ranked higher than
63% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ACOR: 0.50 )
ACOR' s 10-Year Equity to Asset Range
Min: -3.44   Max: 0.74
Current: 0.5

-3.44
0.74
Interest Coverage 3.92
ACOR's Interest Coverage is ranked lower than
54% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACOR: 3.92 )
ACOR' s 10-Year Interest Coverage Range
Min: 3.92   Max: 13.99
Current: 3.92

3.92
13.99
F-Score: 5
Z-Score: 2.16
M-Score: -2.73
WACC vs ROIC
11.07%
9.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.06
ACOR's Operating margin (%) is ranked higher than
88% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. ACOR: 9.06 )
ACOR' s 10-Year Operating margin (%) Range
Min: -9345.93   Max: 12
Current: 9.06

-9345.93
12
Net-margin (%) 4.40
ACOR's Net-margin (%) is ranked higher than
86% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. ACOR: 4.40 )
ACOR' s 10-Year Net-margin (%) Range
Min: -9340.5   Max: 50.67
Current: 4.4

-9340.5
50.67
ROE (%) 3.60
ACOR's ROE (%) is ranked higher than
87% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. ACOR: 3.60 )
ACOR' s 10-Year ROE (%) Range
Min: -92.5   Max: 52.43
Current: 3.6

-92.5
52.43
ROA (%) 2.10
ACOR's ROA (%) is ranked higher than
88% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. ACOR: 2.10 )
ACOR' s 10-Year ROA (%) Range
Min: -109.5   Max: 32.8
Current: 2.1

-109.5
32.8
ROC (Joel Greenblatt) (%) 162.51
ACOR's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. ACOR: 162.51 )
ACOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4354.61   Max: 992.89
Current: 162.51

-4354.61
992.89
Revenue Growth (3Y)(%) 9.00
ACOR's Revenue Growth (3Y)(%) is ranked higher than
81% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. ACOR: 9.00 )
ACOR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.8   Max: 73.6
Current: 9

-61.8
73.6
EBITDA Growth (3Y)(%) 2.60
ACOR's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ACOR: 2.60 )
ACOR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -80.8   Max: 20.5
Current: 2.6

-80.8
20.5
EPS Growth (3Y)(%) -17.90
ACOR's EPS Growth (3Y)(%) is ranked higher than
68% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ACOR: -17.90 )
ACOR' s 10-Year EPS Growth (3Y)(%) Range
Min: -84   Max: -12.4
Current: -17.9

-84
-12.4
» ACOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACOR Guru Trades in Q1 2014

Steven Cohen 370,900 sh (+724.57%)
David Dreman 1,526 sh (+48.88%)
Paul Tudor Jones Sold Out
Jim Simons 217,561 sh (-13.11%)
» More
Q2 2014

ACOR Guru Trades in Q2 2014

Joel Greenblatt 51,262 sh (New)
Steven Cohen 615,600 sh (unchged)
David Dreman Sold Out
Jim Simons 41,500 sh (-80.92%)
» More
Q3 2014

ACOR Guru Trades in Q3 2014

Joel Greenblatt 150,609 sh (+193.80%)
Jim Simons 97,900 sh (+135.90%)
Steven Cohen Sold Out
» More
Q4 2014

ACOR Guru Trades in Q4 2014

Steven Cohen 247,841 sh (New)
Joel Greenblatt 161,650 sh (+7.33%)
Jim Simons 54,100 sh (-44.74%)
» More
» Details

Insider Trades

Latest Guru Trades with ACOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 83.40
ACOR's P/E(ttm) is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 83.40 )
ACOR' s 10-Year P/E(ttm) Range
Min: 6.35   Max: 161.37
Current: 83.4

6.35
161.37
Forward P/E 79.37
ACOR's Forward P/E is ranked higher than
83% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 79.37 )
N/A
PE(NRI) 82.10
ACOR's PE(NRI) is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 82.10 )
ACOR' s 10-Year PE(NRI) Range
Min: 6.35   Max: 157.52
Current: 82.1

6.35
157.52
P/B 2.60
ACOR's P/B is ranked higher than
86% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. ACOR: 2.60 )
ACOR' s 10-Year P/B Range
Min: 2.33   Max: 44.88
Current: 2.6

2.33
44.88
P/S 3.70
ACOR's P/S is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. ACOR: 3.70 )
ACOR' s 10-Year P/S Range
Min: 0.12   Max: 24.53
Current: 3.7

0.12
24.53
PFCF 21.90
ACOR's PFCF is ranked higher than
97% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 21.90 )
ACOR' s 10-Year PFCF Range
Min: 10.97   Max: 130.85
Current: 21.9

10.97
130.85
POCF 19.60
ACOR's POCF is ranked higher than
97% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 19.60 )
ACOR' s 10-Year POCF Range
Min: 9.61   Max: 66.66
Current: 19.6

9.61
66.66
EV-to-EBIT 39.48
ACOR's EV-to-EBIT is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 39.48 )
ACOR' s 10-Year EV-to-EBIT Range
Min: -99.3   Max: 93.5
Current: 39.48

-99.3
93.5
Shiller P/E 77.00
ACOR's Shiller P/E is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 77.00 )
ACOR' s 10-Year Shiller P/E Range
Min: 74.47   Max: 426.56
Current: 77

74.47
426.56
Current Ratio 3.58
ACOR's Current Ratio is ranked higher than
69% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ACOR: 3.58 )
ACOR' s 10-Year Current Ratio Range
Min: 0.71   Max: 22.28
Current: 3.58

0.71
22.28
Quick Ratio 3.34
ACOR's Quick Ratio is ranked higher than
69% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ACOR: 3.34 )
ACOR' s 10-Year Quick Ratio Range
Min: 0.52   Max: 22.28
Current: 3.34

0.52
22.28
Days Inventory 129.29
ACOR's Days Inventory is ranked higher than
86% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 129.29 )
ACOR' s 10-Year Days Inventory Range
Min: 14.56   Max: 332.51
Current: 129.29

14.56
332.51
Days Sales Outstanding 29.28
ACOR's Days Sales Outstanding is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. ACOR: 29.28 )
ACOR' s 10-Year Days Sales Outstanding Range
Min: 28.51   Max: 1465.33
Current: 29.28

28.51
1465.33

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
ACOR's Price/DCF (Projected) is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACOR: 1.60 )
ACOR' s 10-Year Price/DCF (Projected) Range
Min: 1.87   Max: 22.28
Current: 1.6

1.87
22.28
Price/Median PS Value 0.80
ACOR's Price/Median PS Value is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ACOR: 0.80 )
ACOR' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 3.8
Current: 0.8

0.7
3.8
Earnings Yield (Greenblatt) 2.60
ACOR's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. ACOR: 2.60 )
ACOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 7.7
Current: 2.6

1.1
7.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CDG.Germany,
Acorda Therapeutics, Inc. was incorporated on March 17, 1995 as a Delaware corporation. It is a biopharmaceutical company, engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. The Company is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for "Fampyra" and "Kampyra" and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" and "Qutenza" in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.
» More Articles for ACOR

Headlines

Articles On GuruFocus.com
Fv 58 MSN 10 Apr 19 2013 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Acorda Therapeutics Inc. Reports Operating Results (10-K) Mar 01 2011 
Steve Cohen Buys ACOR, DPZ, GXDX, NDN, and OREX Feb 07 2011 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 15,000 Shares Dec 03 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 10,905 Shares Dec 03 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 55,000 Shares Aug 09 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 12,000 Shares Mar 12 2010 


More From Other Websites
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog Apr 13 2015
Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog Apr 13 2015
Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog Apr 13 2015
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog Apr 13 2015
OvaScience (OVAS) Looks Good: Stock Up 8.2% - Tale of the Tape Apr 13 2015
Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog Apr 08 2015
Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog Apr 08 2015
Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog Apr 08 2015
[$$] New Hedge Fund Strategy: Dispute the Patent, Short the Stock Apr 07 2015
Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog Apr 07 2015
Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog Apr 06 2015
Shire, ‘Three’s Company,’ Jersey Pizza: Intellectual Property Apr 05 2015
Innovate or Else: Kyle Bass Strikes Again and Challenges Shire Patents Apr 02 2015
Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog Apr 02 2015
Hayman’s Kyle Bass Targets Shire in New Drug Patent Challenges Apr 02 2015
Cambrex (CBM) Looks Good: Stock Adds 11.6% in Session - Tale of the Tape Apr 01 2015
Raptor Pharmaceuticals (RPTP) in Focus: Stock Falls 9.7% - Tale of the Tape Apr 01 2015
Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog Mar 31 2015
What Makes Novavax (NVAX) a Strong Sell? - Tale of the Tape Mar 31 2015
BioDelivery Sciences International (BDSI) Crumbles: Stock Falls 24.3% - Tale of the Tape Mar 31 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK